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ORIGINAL ARTICLE – MELANOMA
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ABSTRACT
Background. Evidence-based guidelines for follow-up
treatment of American Joint Committee on Cancer (AJCC)
stages 1B to 2C melanoma patients are lacking. The
MELanoma FOllow-up study is an international phase 3
randomized trial, and the 3-year interim data were recently
reported from the Netherlands. The study was undertaken
concurrently with a British cohort for comparison and
validation of the Dutch study.
Methods. The study enrolled and stratified 207 patients by
AJCC stage. The conventional schedule group (CSG;
n = 103) cohort was reviewed as per UK guidelines. The
experimental schedule group (ESG; n = 104) cohort was
reviewed in a reduced-frequency nurse-led, consultant-su-
pervised clinic. Quality of life (QoL) was measured at
baseline (T1), a 1 year (T2), and at 3 years (T3) using the
State-Trait Anxiety Inventory, the Cancer Worry Scale, the
Impact-of-Event Scale, and the Mental and Physical
Component scales (PCS/MCS) of the RAND-36.
Results. Of the 207 QoL questionnaires, 170 (82.1%) were
completed at T3. Both cohorts expressed high satisfaction
([ 93%) with their regimens. At T3, no significant group
effect was found on any patient-reported outcome mea-
sures scores, indicating no QoL difference between the
follow-up protocols. Recurrence had developed in 33
patients Conventional follow-up (CFU), 16 [15.5%];
Experimental follow-up (EFU), 17 [16.3%]. Self-exami-
nation was the method of detection for 12 ESG patients
(70.6%) and 11 CSG patients (68.8%). The melanoma-
specific survival was identical.
Conclusion. The UK 3-year data were consistent with the
previous Dutch report. The reduced follow-up strategy was
shown to be safe, with significant resource usage benefits
for national cancer services. Patient anxiety levels were not
increased by a less-intensive follow-up regimen, and
acceptance was high. The study data indicate that patient
self-examination is very effective for recurrence detection.
Primary cutaneous melanoma is the fifth most common
cancer in the UK, accounting for 4% of all new cancer
cases, and since the early 1990s, melanoma incidence rates
have more than doubled (128%).1 The incidence rates for
melanoma skin cancer are projected to rise by 7% in the
UK between 2014 and 2035, to 32 cases per 100,000
individuals by 2035.
Melanoma disproportionately affects a younger demo-
graphic relative to other solid human cancers, with a
melanoma diagnosis for nearly half of the patients before
their 65th birthday. Furthermore, the prognosis for mela-
noma generally is very good2 (overall 10-year survival rate
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of 90%). It is estimated that more than 150,000 people in
the UK currently are living with the diagnosis of mela-
noma. Therefore, long-term follow-up arrangements and
patient education for early detection has become a key
survivorship issue.
The routine use of sentinel lymph node biopsy (SLNB)
for accurate staging of melanoma patients has been incor-
porated into most international melanoma guidelines.
Although the purpose of SLNB may have subtly but firmly
shifted from identifying high-risk patients requiring a
completion lymph node dissection to stratifying high-risk
patients for adjuvant systemic therapy,3–5 the initial out-
come remains the same for the majority of patients in that
no further treatment is indicated because their SLNB shows
no evidence of melanoma metastasis. However, these
patients still require follow-up evaluation because the risk
of locoregional or distant spread remains a possibility.
The main aims of follow-up programs for melanoma
patients are thought to be early detection of recurrences and
prompt recognition of subsequent primary melanoma. Other
aims are patient reassurance and evaluation of the surgical
treatment outcome. Several groups have attempted to
determine the most effective follow-up schedule by testing
their current follow-up schedule or by estimating a new
follow-up schedule on the basis of retrospective data.6–9
Most proposed follow-up schedules are based on the
premise that the annual risk of recurrence increases with
advancing American Joint Committee on Cancer (AJCC)
stage.10–12 Almost 90% of recurrences are experienced in
the first 3 years after the primary diagnosis for intermediate
and thick melanomas,7,9,13–15 and the risk of recurrence
after 10 years of follow-up evaluation is low (2.4%).16 For
thin melanomas, the risk of recurrence is very low in
general, although the patients who do go on to experience a
recurrence generally present after a significant delay.17
Accordingly, national guidelines committees find it chal-
lenging to devise simple follow-up schedules for
melanoma patients.
The MELanoma FOllow-up (MelFO) study is an inter-
national phase 3 randomized controlled trial (RCT), and
the 3-year interim data were reported recently from the
Netherlands.18 This clinical trial aimed to provide an evi-
dence basis for the follow-up evaluation of cutaneous
melanoma patients with no evidence of sentinel node
metastasis. The primary end points of this trial are related
to quality of life (QoL), cancer worry, and stress-related
symptoms. The trial was undertaken concurrently in the
UK to compare and validate the findings of a Dutch study
analyzing the primary end points in an English-speaking
cohort, with the additional predetermined intention of
ultimately combining the international data set to assess the
secondary end points of recurrence rates and survival
(patient safety).
The trial hypothesis was that QoL does not decrease
with a reduced-intensity AJCC stage-adjusted follow-up
regimen relative to the UK National Institute for Health
and Care Excellence (NICE)-recommended follow-up
regimen for AJCC stages 1B to 2C melanoma patients
staged with SLNB. The predetermined interim analysis
point was 3 years to ensure patient compliance with the
protocol and patient safety in terms of recurrence rates.
Accordingly, we report the results of a planned 3-year UK
interim analysis of the data.
METHODS
Study Design
The detailed methods of this multicenter, randomized
clinical trial (NCT0108004), initiated by the Department of
Surgical Oncology at the University Medical Center of
Groningen (UMCG), have been described previously.19
The participants were randomized into two groups: one
group who followed the conventional schedule recom-
mended in the UK NICE melanoma guidelines20 and one
group whose follow-up evaluation was an AJCC stage-
adjusted reduced schedule (Table 1).
The primary end point for this study was patient QoL.
The secondary end points were recurrence rates, site of
recurrence, and method of detection, in addition to standard
outcomes data such disease-specific and overall survival
findings. The study was approved by the Cambridgeshire
research ethics committee service (Rec Ref: 10/H0306/18;
IRAS number: 43852).
Patients and Procedure
The inclusion criteria specified SLNB-negative mela-
noma patients with AJCC stages 1B to 2C disease who had
undergone surgery with curative intent between 2010 and
2015. The study excluded patients younger than 18 years
or older than 85 years, those not able to speak English and/
or unable to complete the questionnaires, and those who
had another malignancy.
After giving informed consent, eligible patients were
randomized into the conventional group (CSG) or the
experimental schedule group (ESG) in a 1:1 manner and
stratified according to AJCC stage. The Netherlands
Comprehensive Cancer Organization (IKNL) was the
coordinating clinical trial center for this study and per-
formed the randomization of the UK patients.
The patients completed questionnaires at study entry
shortly after diagnosis (T1), after 1 year (T2), and 3 years
later (T3). Patients were excluded from T2 or T3 if they
withdrew consent or died. Clinicians provided follow-up
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information on the disease status and overall performance
status of all the patients during the 3 years of the study or
until the patients experienced a recurrence, a second pri-
mary tumor, or death.
The current study focused on comparisons between the
T1, T2, and T3 time points, with QoL as a primary end
point. Recurrence detection rates, clinical outcomes and
patient satisfaction rates, and schedule compliance were
secondary end points.
QOL/PROMs Instruments
At T1, the patients answered questions on gender, age,
level of education, relationship status, daily activities, and
comorbidities. At T1 and T3, they answered questions on
schedule satisfaction, frequency of self-inspection, and
number of melanoma-related general practitioner/primary
care physician (GP) visits. The treating clinicians gave
diagnostic information (primary melanoma site, Breslow
thickness, ulceration, AJCC classification) and follow-up
information (date of every outpatient visit, date and loca-
tion of recurrence, date and cause of death). The patients
completed the following patient-reported outcome mea-
sures (PROMs) at T1, T2, and T3:
1. The State-Trait Anxiety Inventory-state version
(STAI-s), a 20-item questionnaire measuring the
transitory emotional condition of stress or tension
perceived by the patient. Items are scored on a 4-point
scale ranging from 1 (not at all) to 4 (very much)
(range, 20–80).21
2. The 3-item Cancer Worry Scale (CWS) measuring
concerns about cancer developing again and the impact
on daily activities.22–24 Higher scores mean more
worries (range, 3–12).
3. The 15-item Impact-of-Event Scale (IES) evaluating
the extent to which patients experience life hazards, in
this case having a melanoma, in terms of avoidance
and intrusion.25, 26 A higher score (range, 0–75) cor-
responds to a higher level of stress response symptoms.
4. The RAND-36, a 36-item health-related QoL ques-
tionnaire, of which the mental component score (MCS)
and the physical component summary scores (PCS)
were used. The summary scores are standardized with
a mean of 50 and a standard deviation of 10.27
Statistical Analysis
Statistical analyses were performed using IBM SPSS
statistics version 22 (SPSS Inc; Chicago, IL, USA) and
STATA v.12 (StataCorp, College Station, TX, USA). The
sample size and power analyses have been described previ-
ously.19 Patient characteristics were described, and
comparisons between study groups were performed using
independent t tests, the Mann–Whitney U test, Chi square
tests, or Fisher’s exact tests, as appropriate. To examine dif-
ferences between groups and time differences in PROMs,
t tests and paired t tests were performed. When a difference
was found to be statistically significant, effect sizes were
computed to examine clinical relevance. Clinicians consider
effect size values of 0.5 or higher to be large, those between
0.3 and 0.5 to be moderate, and those lower than 0.3 to be
small.28 Kaplan–Meier log-rank tests were performed to
compare groups in terms of recurrence-free survival and
disease-specific survival. In all the statistical analyses, p val-
ues lower than 0.05 were considered statistically significant.
RESULTS
Enrolment of the patients and their outcomes are sum-
marized in the Consolidated Standards of Reporting Trials
(CONSORT) diagram (Fig. 1). In summary, 534 patients
TABLE 1 Frequency of follow-up visits for the conventional follow-up schedule as recommended by the UK NICE Melanoma Guideline,20 and
a reduced and stage-adjusted experimental follow-up schedule
Conventional follow-up schedule Difference at 5 years (n visits) Experimental follow-up schedule
Yearsa 1 2 3 4 5 6–10 Yearsa 1 2 3 4 5 6–10
AJCC stage Visits per year AJCC stage Visits per year
1B 4 4 4 2 2 0 11 IB 1 1 1 1 1 1
2A 4 4 4 2 2 1 9 IIA 2 2 1 1 1 1
2B 4 4 4 2 2 1 6 IIB 3 3 2 1 1 1
2C 4 4 4 2 2 1 6 IIC 3 3 2 1 1 1
AJCC American Joint Committee on Cancer
aYear after surgery for primary melanoma, including staging with sentinel node biopsy
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were assessed for eligibility, and 114 did not meet the
inclusion criteria. Ultimately, 207 of the 420 eligible
patients (response rate, 49.2%) were enrolled in the study
(99 women and 108 men; median age, 62 years;
interquartile range [IQR], 52–69 years) and stratified by
AJCC stage. The conventional schedule group (CSG;
n = 103) cohort was reviewed clinically as per national
guidelines.20 The experimental schedule group (ESG;
n = 104) cohort was reviewed according to a reduced-fre-
quency schedule (Table 1). For both cohorts, follow-up
evaluation was performed in a cancer nurse specialist
(CNS)-led/consultant-supervised melanoma clinic in the
combined skin cancer outpatient department using struc-
tured patient education for self-examination techniques at
the time of enrolment. The patient education component
for self-examination was reinforced by the CNS at each
scheduled visit.
Table 2 describes the distribution of the patients and
their tumors between the two experimental cohorts. The
two cohorts were well-matched for age, education/marital/
employment statuses, and tumor stage. Gender was an
exception, with significantly more women in the ESG
cohort (55.8% vs. 39.8%; p = 0.02).
At the T3 time point, 154 (88.2%) of 170 of patients
completed the follow-up questionnaires. Table 3 demon-
strates that after 3 years, no significant group difference
was found in terms of patient satisfaction with the follow-
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FIG. 1 Consort diagram for Mel-FO
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rate higher than 93%. Nearly all the patients in both groups
reported examining their skin and lymph node fields, and
both groups were performing this with a similar frequency.
Table 4 shows that the overall compliance with the
follow-up schedules was high at the T2 and T3 time points
(68.5% and 66.5%, respectively). At T2, no significant
group difference in overall compliance with the follow-up
schedule was observed (ESG, 69.9% vs. CSG, 67%).
However, significantly more scheduled visits were made by
the ESG patients (25.2%) than by the CSG patients (11%),
and significantly more scheduled visits were unattended by
the CSG patients (22%) than by the ESG patients (4.9%).
This trend was statistically significant (Pearson Chi square
test [df = 2], p\ 0.0001; test for trend [df = 1],
p = 0.0006). At T3, no significant group effect was
observed with the schedule compliance rate (CSG, 71.8%
vs. ESG, 61.2%). Furthermore, no significant differences
between the groups were detected in the number of
unscheduled or missed follow-up appointments. Of the 31
patients who did access an additional clinic in the
12 months before the T3 time point, 38 (81.6%) did this
only once. At the same time, only 4.6% indicated that they
TABLE 2 Patient and melanoma characteristics at randomization T1 for the study groups
Characteristics Total (n = 207)
n (%)
Conventional schedule (n = 103)
n (%)
Experimental schedule (n = 104)
n (%)
p Value
Sex Female 99 (47.8) 41 (39.8) 58 (55.8) 0.02
Male 108 (52.2) 62 (60.2) 46 (44.2)
Age (years) B 55 68 (32.9) 36 (35.0) 32 (30.8) 0.46
56–64 62 (29.9) 33 (32.0) 29 (27.9)
65? 77 (37.2) 34 (33.0) 43 (41.3)
Level of education Primary school 2 (1.0) 2 (1.9) 0 (0.0) 0.34
Secondary/high 133 (64.3) 70 (68.0) 63 (60.6)
Diploma 27 (13.0) 11 (10.7) 16 (15.4)
University 42 (20.3) 18 (17.5) 24 (23.1)
Unknown 3 (1.4) 2 (1.9) 1 (1.0)
Relationship status Without partner 34 (16.4) 13 (12.6) 21 (20.2) 0.21
With partner 172 (83.1) 89 (86.4) 83 (79.8)
Unknown 1 (0.5) 1 (1.0) 0 (0.0)
Daily activities Employed 95 (45.9) 52 (50.5) 43 (41.3) 0.41
Not employed 110 (53.1) 50 (48.5) 60 (57.7)
Unknown 2 (1.0) 1 (1.0) 1 (1.0)
Presence of comorbidities No 119 (57.5) 60 (58.3) 59 (56.7) 0.37
Yes 86 (41.5) 43 (41.7) 43 (41.4)
Unknown 2 (1.0) 0 (0.0) 2 (1.9)
Primary melanoma Head and neck 34 (16.4) 15 (14.6) 19 (18.3) 0.22
Trunk 82 (39.6) 47 (45.6) 35 (33.7)
Lower extremity 45 (21.8) 23 (22.3) 22 (21.1)
Upper extremity 46 (22.2) 18 (17.5) 28 (26.9)
Breslow thickness \ 1.00 47 (22.7) 21 (20.4) 26 (25.0) 0.47
1.00–2.00 103 (49.8) 55 (53.4) 48 (46.2)
2.01–4.00 44 (21.2) 19 (18.4) 25 (24.0)
[ 4.00 13 (6.3) 8 (7.8) 5 (4.8)
Ulceration No 166 (80.2) 85 (82.5) 81 (77.9) 0.40
Yes 41 (19.8) 18 (17.5) 23 (22.1)
AJCC classification 1B 136 (65.7) 68 (66.0) 68 (65.4) 0.97
2A 33 (15.9) 16 (15.5) 17 (16.3)
2B 33 (15.9) 16 (15.5) 17 (16.4)
2C 5 (2.4) 3 (2.9) 2 (1.9)
AJCC American Joint Committee on Cancer
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had visited their GP in the preceding 6 months. The
majority of the extra visits were for other suspicious
lesions, which eventually were diagnosed as benign lesions
or non-melanoma skin cancers (16/38 patients, 42.1%). Of
the 38 patients, 12 (31.6%) chose to rearrange their
appointments to suit their lifestyle (including 1 pregnancy)
rather than for any specific cancer concerns. The remaining
patients (26.3%) were concerned about signs or symptoms
related to cancer recurrence.
Patient-Reported Outcome Measures
The QoL questionnaires were completed by 184 patients
at T2 (94 ECG and 90 CSG patients) and 170 patients at T3
(85 ESG and 85 CSG patients). Table 5 describes the QoL/
PROMs data. At T1, the two groups did not differ signif-
icantly in terms of QoL/PROMs measurements, except for
the CWS. The CSG cohort had a significantly higher CWS
than the ESG cohort (8.4 vs. 7.4; p = 0.02). At T2, no
significant group effect on the IES, CWS, STAI, or RAND-
36 scores was found, indicating no difference in QoL
between the follow-up protocols. Comparison of the T1
and T2 QoL data showed a significant improvement in the
CWS and IES for the CSG cohort (p\ 0.001 and
p = 0.006, respectively), indicating that the patients were
experiencing fewer stress response symptoms and less
worry related to their cancer in the CSG cohort after 1 year
than shortly after diagnosis.
The ESG cohort showed no difference in QoL scores
between T1 and T3, except for the IES (p = 0.007),
TABLE 3 Follow-up related questions at 3 years (T4)
Follow-up related questions at 3 years Total (n = 154)
n (%)
Conventional schedule (n = 79)
n (%)




Yes 145 (94.2) 74 (93.7) 71 (94.6) 0.92
No 5 (3.2) 3 (3.8) 2 (2.7)
Missing 4 (2.6) 2 (2.5) 2 (2.7)
Reason dissatisfaction
Wants more visits 2 (1.3) 1 (1.3) 1 (1.3) 0.62
Wants fewer visits 1 (0.6) 1 (1.3) 0 (0.0)
Melanoma-related GP visits (last 6 months)
None 65 (42.2) 29 (36.7) 36 (48.0) 0.31
Every week 6 (3.9) 3 (3.8) 3 (4.0)
Once every month 0 (0.0) 0 (0.0) 0 (0.0)
Every 3 months 1 (0.6) 0 (0.0) 1 (1.3)
Less than every 3 months 0 (0.0) 0 (0.0) 0 (0.0)
Never 1 (0.6) 0 (0.0) 1 (1.3)
Unknown 81 (52.6) 47 (59.5) 34 (45.3)
Frequency of skin self-inspection
Every week 54 (35.1) 26 (32.9) 28 (37.3) 0.72
Every month 74 (48.0) 42 (53.1) 32 (42.7)
Once every 3 months 15 (9.7) 7 (8.9) 8 (10.7)
Less than every 3 months 7 (4.6) 3 (3.8) 4 (5.3)
Never 1 (0.7) 0 (0.0) 1 (1.3)
Unknown 3 (1.9) 1 (1.3) 2 (2.7)
Frequency of lymph node self-inspection
Every week 45 (29.2) 20 (25.3) 25 (33.3) 0.18
Every month 78 (50.7) 44 (55.7) 34 (45.3)
Once every 3 months 16 (10.4) 8 (10.1) 8 (10.7)
Less than every 3 months 9 (5.8) 2 (2.5) 7 (9.3)
Never 2 (1.3) 2 (2.5) 0 (0.0)
Unknown 4 (2.6) 3 (3.8) 1 (1.3)
GP melanoma-related general practitioner/primary care physician
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indicating that the ESG cohort was experiencing fewer
stress response symptoms during the first year. At T3, no
significant group effect on the IES, CWS, STAI, or RAND-
36 scores was found, indicating no difference in QoL
between the follow-up protocols. Comparison of the T1
and T3 data showed that both the ESG and CSG cohorts
were experiencing significantly fewer stress response
symptoms and less cancer worry after 3 years, indicating
that the sustained improvement in QoL observed in the two
groups at T2 had been maintained at T3. Effect size cal-
culations (Cohen’s d) indicated that the clinical importance
of the observed statistically significant between-group
difference in CWS at T1 was small (effect size, 0.32). The
effect size calculated on statistically significant time dif-
ferences ranged between small (effect size of 0.29 for the
difference between T1 and T2 in IES in the ESG cohort)
and clinically important (ES of 0.88 for the difference
between T1 and T3 in IES in the CSG cohort) and showed
that improvements in CWS and stress response symptoms
measurements became greater as time passed, particularly
in the ESG cohort.
Melanoma Recurrences and Deaths During the 3-Year
Follow-Up Period
At T3, 11 patients in the ESG cohort and 9 patients in
the CSG cohort had died. The majority of the deaths were
melanoma-specific (7/9 [77.8%] in the CSG cohort and
8/11 [72.7%] in the ESG cohort), and the melanoma-
specific mortality did not differ between the two groups.
Similarly, the two groups did not differ significantly in
overall detected recurrence rates or progression-free sur-
vival (ESG, 17/104 [16.3%] vs. CSG, 16/103 [15.1%]). In
both cohorts, more than two thirds of the recurrences and
TABLE 4 Follow-up schedule compliancy and detection of recurrences
Total (n = 207)
n (%)
Conventional schedule (n = 103)
n (%)
Experimental schedule (n = 104)
n (%)
p Value
Schedule compliance (0–1 years)
Missed visits 27 (13.3) 22(22) 5 (4.9) For trend
On schedule 139 (68.5) 67(67) 72 (69.9) 0.0001
Extra visits 37 (18.2) 11 (11) 26 (25.2)
Off trial 4 3 1
Schedule compliance (2–3 years)
Missed visits 19 (11.2) 9 (10.6) 10 (11.8) NS
On schedule 113 (66.5) 61 (71.8) 52 (61.2)
Extra visits 38 (22.3) 15 (17.6) 23 (27.1)
Off trial 37 18 19
Site of initial recurrence
Local/in-transit 6 (18.2) 0 6 (23.5)
Regional nodes 8 (24.2) 4 (25.0) 4 (23.5)
Distant 10 (30.3) 7 (43.8) 3 (17.6)
Multiple sites 5 (15.2) 3 (18.8) 2 (11.8)
Second melanoma 4 (12.1) 2 (12.5) 2 (11.8)
Second malignancy 3 3 0
Detection
Patient 23 (69.7) 11 (68.8) 12 (70.6) NS
Relative 1 (3) 1 (6.3) 0
Clinician 9 (27.3) 4 (25) 5 (29.4)
AJCC stage (8th ed)
1A 2 (6.1) 1 (6.3) 1 (5.9) NS
1B 9 (27.3) 3 (18.8) 6 (35.3)
2A 9 (27.3) 4 (25) 5 (29.4)
2B 10 (30.3) 6 (37.5) 4 (23.5)
2C 3 (9.1) 2 (12.5) 1 (5.9)
NS not significant; AJCC American Joint Committee on Cancer
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second melanomas were detected by the patient initially
(Table 4). The CSG cohort had a greater proportion of
distant recurrences than the ESG cohort, which had a
greater proportion of locoregional recurrences at the initial
sites of recurrence, although this difference was not sta-
tistically significant (p = 0.095, Fisher’s exact test). No
AJCC initial stage-specific bias was observed between the
two cohorts in terms of recurrence rates (Chi square test for
trend, p = 0.254).
DISCUSSION
This study showed that 3 years after staging with a
negative SLNB, the AJCC stages 1B to 2C cutaneous
melanoma patients assigned to the reduced, stage-adjusted
follow-up schedule (ESG) did not differ in levels of anxi-
ety, cancer worry, or mental health-related QoL from the
patients assigned to the follow-up schedule as currently
advised in the UK NICE melanoma guideline.20 Moreover,
the ESG patients reported significantly lower levels of
cancer worry than the CSG patients from the earliest point
of the study (at inclusion). This study demonstrated that the
reduced follow-up schedule was safe, with no difference in
progression-free or disease-specific survival. These results
support our hypotheses of no differences in PROMs,
recurrences, or deaths between the study groups.
These results mirror the findings of the Dutch group,
which recently reported very similar results in 2019.18 As
in the Dutch study, our data indicated that the large
majority of patients were satisfied with their follow-up
regimen regardless of the schedule. The data suggest that
patients undergo a period of adjustment during the first
12 months of the follow-up period after treatment before
they settle into the follow-up routine. Although the patients
in this study were overwhelmingly satisfied with their
follow-up regimens, in the early months, they were more
inclined to seek extra appointments in the reduced-fre-
quency ESG schedule (mostly to discuss wound-healing
issues or to repeat the education session rather than for true
cancer concerns). The others were more likely to miss their
appointments in the higher-frequency CSG schedule,
mostly due to clashes with other lifestyle events, such as
vacations or work. During this period, both sets of patients
demonstrated significantly reduced levels of worry and
fewer cancer stress response symptoms after the initial
12 months of follow-up evaluation, which then persisted
through to 3 years.





















Conv 32.8 ± 17.8 31.6 ± 10.9 0.62 0.84 0.53 (Conv) 33.5 ± 15.9 0.65 0.82 (Conv)
Expl 34.2 ± 19.7 32.0 ± 10.9 0.28 (Exp) 35.0 ± 22.9 0.79 (Exp)
Cancer Worry
Scale




0.32 \ 0.001 (Conv)
ES = 0.71




Conv 26.6 ± 10.8 22.8 ± 9.1 0.50 0.75 0.006 (Conv)
ES = 0.47
19.5 ± 7.0 0.47 \ 0.001
(Conv)
ES = 0.88
Exp 25.6 ± 9.9 22.9 ± 9.0 0.007 (Exp)
ES = 0.29





Conv 50.9 ± 9.7 53.0 ± 7.8 0.86 0.31 0.02 (Conv) 53.0 ± 9.3 0.99 0.15 (Conv)




Conv 49.1 ± 9.6 50.4 ± 10.6 0.97 0.35 0.23 (Conv) 50.9 ± 10.3 0.77 0.11 (Conv)
Expl 49.0 ± 10.2 49.0 ± 11.1 0.93 (Exp) 50.4 ± 9.1 0.15 (Exp)
Conv conventional, Exp experimental, ES effect size (Cohen’s d)
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This study demonstrated significantly less cancer worry
in the ESG cohort than in the CSG cohort at study inclu-
sion, although the effect size calculation suggested that the
difference was small and not clinically relevant, and
therefore unlikely to have biased the results. Previous
studies have suggested that 50% of patients report high
levels of anxiety before and during outpatient clinic vis-
its.29 Our data suggest that the stress response and worry
symptoms decrease over time from diagnosis regardless of
the follow-up schedule, particularly where no recurrence is
detected. Effect size calculations showed that the decreases
in clinical importance ranged from small to high in both
groups.
Unlike the Dutch study, the two groups in the current
study did not differ significantly in the proportion of
patients paying extra visits to the specialist clinic. More
than 80% of the patients who did access an additional clinic
had visited the clinic only once, whereas very few patients
(\ 5%) had visited their GP in the preceding 6 months.
Our data suggest that the reason for these extra visits may
have been increased awareness of suspicious lesions, pos-
sibly resulting from effective education on self-
inspection.9,13–15,29–33.
The current 3-year results show that the number of
recurrences and second primary melanomas as well as the
time until detection for the patients with AJCC stages 1B to
2C disease was independent of the assigned follow-up
schedule, which is consistent with the Dutch 3-year MelFO
results.18 Almost half of recurrences (16/33) were detected
within the first 12 months. Consistent with previous liter-
ature, this shows that the highest proportion of melanoma
recurrences and second primaries is detected during the
first year of follow-up evaluation and that the proportion
declines in the following years.7,13–15
This study also showed that the patients were most
likely to detect their recurrences first, with 75.8% of all
recurrences detected this way. This is consistent with
observations of previously published studies.14,15,29 In this
study, we observed a trend toward the earlier AJCC stage 3
recurrences being detected more frequently in the ESG
cohort, which suggests that patient education for self-ex-
amination is very effective. Crucially, the study found no
evidence of diagnostic delay, with the recurrence-free
survival intervals identical in both cohorts. Overall, the
3-year recurrence rate in the current study was 15.9%,
which is comparable with the Dutch MelFO cohort rate of
13.4% and that of previously published literature.13
One limitation of this study was that the physical
examination-based follow-up regimen may be deemed less
than adequate for the care of future melanoma patients.
Since the start of this trial, effective systemic therapy has
become routinely available to patients with advanced
melanoma.34–36 Our protocol for this trial did not mandate
any radiologic surveillance of either cohort because there
was no convincing evidence showing it to be effective and
no consensus on the topic had been reached. However,
future follow-up regimens for patients receiving adjuvant
systemic therapy likely will include initial radiologic
screening and serial surveillance scans to detect asymp-
tomatic stage 4 recurrences. Regardless, the majority of
melanoma patients remain AJCC stage 1B/2A (84.1% of
the current cohort) after their initial surgical treatment and
staging with SLNB, and these patients would be unlikely to
require any further systemic treatment. For this group, the
reduced-intensity follow-up schedule still would be valid,
and it was encouraging that 75% of all recurrences were
detected by the patients themselves.
The current study had several limitations. First, due to
the pragmatic design and the open-access clinic policy
mandated by both the trial protocol and the ethics com-
mittee, one third of the patients did not strictly adhere to
the follow-up protocol. Similarly, the dropout rates for the
Qol/PROMs measurements were 11% at T2 and 18% at T3.
This was higher than the predicted 10% rate envisaged in
the trial design.
Second, the power analysis showed that 89 patients per
group were needed. We started with 103 patients in the
CGS cohort and 104 patients in the ESG cohort, but due to
the dropout during 3 years, the number of patients analyzed
at T3 was slightly lower than envisaged (85 per group).
However, no differences in sociodemographic or illness-
related variables were found between the participants in the
two study groups at T1.
Third, due to the low event rate in both cohorts, some of
the analyses performed, particularly those involving clini-
cal disease outcomes, should be interpreted carefully.
Finally, 213 patients of the eligible cohort declined to
enroll into this study. For the majority of these patients
([ 85%), the distance required for travel to the trial center
for follow-up evaluation was the reason given for refusing
to participate (data not shown).
CONCLUSION
The interim results of this phase 3 RCT at 3 years,
undertaken in a native English-speaking cohort, appear to
have validated the findings of our Dutch colleagues who
undertook this study in the Netherlands using the same
protocol.18 The UK MelFO study seems to support the
notion that a reduced stage-adjusted follow-up schedule is
an appropriate and safe approach for AJCC stages 1B to 2C
melanoma patients after staging with sentinel biopsy in
terms of QoL, patient satisfaction, and disease safety at
3 years. We anticipate reporting the final outcome of the
study at the end of 2020, with the data from the
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Netherlands and the UK combined to ensure adequate
power to detect any difference in recurrence rates, thereby
dispelling any lingering concerns about patient safety with
a reduced follow-up regimen.
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